Casey Petra M, Cerhan James R, Pruthi Sandhya
Department of Obstetrics and Gynecology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Mayo Clin Proc. 2008 Jan;83(1):86-90; quiz 90-1. doi: 10.4065/83.1.86.
The clinical impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more than a quarter of a million women are diagnosed as having breast cancer in the United States annually. Substantial changes to OC formulations have been made during the past decade, and this review focuses on recent OC trends and risks and benefits. We also have a better understanding of how estrogen affects breast carcinogenesis; research on this topic is ongoing and has the goal of decreasing breast cancer incidence and mortality.
鉴于口服避孕药（OC）是最常用的避孕药物，且在美国每年有超过25万女性被诊断患有乳腺癌，因此OC使用与乳腺癌风险之间关联的临床影响十分重要。在过去十年中，OC配方有了实质性变化，本综述重点关注OC的近期趋势以及风险和益处。我们也对雌激素如何影响乳腺癌发生有了更好的理解；关于这一主题的研究正在进行中，目标是降低乳腺癌的发病率和死亡率。
